Baseline chest CT-based deep learning for predicting subsequent spinal tuberculosis in patients with pulmonary tuberculosis: a two-center retrospective study
To develop and internally evaluate a deep learning model using pretreatment baseline chest CT to classify documented subsequent spinal tuberculosis (STB) status during available follow-up in patients with pulmonary tuberculosis (PTB). This two-center retrospective study included 1,668 consecutive eligible patients with PTB and no documented STB at baseline. Records from January 2010 to October 2025 provided up to 15 years of follow-up. All eligible patients were retained without outcome-based sampling. The observed 25% STB fraction was not imposed by the study design. Patients were stratified by center and outcome into training (n = 1,168), validation (n = 252), and test (n = 248) sets. ResNet18, AlexNet, DenseNet121, and ResNet50 were compared using single-slice CT regions of interest. Architecture and classification threshold selection used validation data. The cut-off was fixed using the validation-set Youden index before test evaluation. No clinical-model comparison was performed. Calibration and decision curve analysis (DCA) were exploratory because follow-up varied and no prediction horizon was prespecified. The cohort included 417 patients with documented subsequent STB and 1,251 without. ResNet18 achieved the highest validation-set area under the ROC curve (AUC) and was selected for final evaluation. Its training, validation, and test AUCs were 0.858 (95% CI 0.833–0.883), 0.733 (95% CI 0.656–0.811), and 0.784 (95% CI 0.720–0.848), respectively. Test-set accuracy, sensitivity, specificity, precision, and F1-score were 0.746, 0.694, 0.763, 0.494, and 0.577. Test AUC was significantly higher than ResNet50, but not AlexNet or DenseNet121, after multiplicity correction. Calibration was imperfect. Qualitative Grad-CAM examples showed activation in pulmonary lesion-related and adjacent extrapulmonary regions. Baseline chest CT-based deep learning showed moderate discrimination for documented subsequent STB during available follow-up, rather than risk at a defined horizon. External validation with standardized outcome ascertainment and complete event and censoring dates is required before clinical application.
Authors
- Saimaitikari Abudoubari
- Abudouresuli Tuersun
- Mireayi Tudi
- Xin Qiao
- Nuermaimaijiang Abudouwufu
- Lijuan Da
- Yi You
- Ya Qiu
Institutions
- Kashi University (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1186/s40001-026-05519-x
- Primary Topic
- Infectious Diseases and Tuberculosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Xinjiang Province